Oncology Learning Network

Dr Percival on New AML Treatments by HMP Global

In an interview with Oncology Learning Network, Udai Banerji, MD, NIHR Professor of Molecular Cancer Pharmacology, The Institute of Cancer Research, London, United Kingdom, discussed the findings and clinical significance of a phase 1 trial evaluating the use of VS-6766, a RAF/MEK inhibitor, plus defactinib, a FAK inhibitor, in patients with KRAS-mutant ovarian cancer.

Veena Shankaran, MD, MS, Discusses Financial Hardships in Patients With Metastatic CRC by HMP Global

What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress by HMP Global

Dr Jabbour on Management of Ph+ and Ph-like ALL by HMP Global

Christopher Crane, MD, Discusses Benefits of Long-Course Vs Short-Course RT for Rectal Cancer by HMP Global

CAR T-Cell Therapy Promising for Relapsed, Refractory Large B-Cell NHL by HMP Global

Long-term Follow Up of First-line NALIRIFOX in Pancreatic Cancer by HMP Global

Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML by HMP Global

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.

Faster Corticosteroid Tapering Safe in Relapsed/Refractory MM by HMP Global

BCMA-Directed CAR-T Therapy Shows Promise in Heavily Pretreated MM by HMP Global

Triplet Combo Well-Tolerated, Effective for IDH1-Mutated AML by HMP Global

Shirish Gadgeel, MD, Discusses Follow-Up Results of Pembrolizumab with Chemotherapy for NSCLC by HMP Global

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance (COA) discusses how, in the face of the COVID-19 pandemic, COA is standing strong and readjusting to cater to the needs of community oncologists nationwide.

In this inaugural episode of Sarcoma Sound Bites with Brian and Bob, an Oncology Learning Network Podcast, join Brian Van Tine, MD, PhD, Sarcoma Program Director, Washington University, and Robert “Bob” Maki, MD, PhD, Northwell Health Cancer Center Institute, New York, as they discuss the challenges of treating tenosynovial giant cell tumors (TGCTs), and how the treatment landscape for TGCT has ev...

Joshua M. Bauml, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, shares first-hand insight on the management of patients with lung cancer during the COVID-19 pandemic.

In an interview with Oncology Learning Network, Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, talks about the clinical significance and findings of the SWOG S0307 trial.

In an interview with Oncology Learning Network, Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, discusses ways that healthcare providers can encourage patient enrollment in cancer clinical trials.

Julie R. Gralow, MD, Clinical Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Washington, discusses findings from the SWOG S0307 trial, which looked at the occurrence of fractures in patients with breast cancer receiving high-dose bisphosphonates to prevent metastases.

Michiel Van de Sande, MD, Discusses Multidisciplinary Approach to Treating TGCT by HMP Global

Post-Transplant TKI Salvage Therapy Provides Significant Survival Benefit Following Relapse in CML by HMP Global

BTK Inhibitors Important in the Treatment Landscape of MCL by HMP Global

In an interview with Oncology Learning Network, Randall A. Oyer, MD, Association of Community Cancer Centers (ACCC) President, discusses the basis and goal of his presidency theme, entitled “Community Oncology Can Close the Gap in Cancer Research.”

Direct-to-Patient Strategies in Multiple Myeloma Care by HMP Global